<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitroprusside: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitroprusside: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitroprusside: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11844" href="/d/html/11844.html" rel="external">see "Nitroprusside: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12648" href="/d/html/12648.html" rel="external">see "Nitroprusside: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709173"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nitropress: After reconstitution, nitroprusside is not suitable for direct injection. The reconstituted solution must be further diluted in dextrose 5% injection before infusion.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside can cause precipitous decreases in blood pressure. In patients not properly monitored, these decreases can lead to irreversible ischemic injuries or death. Use only when available equipment and personnel allow blood pressure to be continuously monitored.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cyanide toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Except when used briefly or at low (less than 2 mcg/kg/min) infusion rates, nitroprusside injection gives rise to important quantities of cyanide ion, which can reach toxic, potentially lethal levels. The usual dose rate is 0.5 to 10 mcg/kg/min, but infusion at the maximum dose rates should never last more than 10 minutes. If blood pressure has not been adequately controlled after 10 minutes of infusion at the maximum rate, terminate administration immediately. Although acid-base balance and venous oxygen concentration should be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F202198"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nipride RTU;</li>
<li>Nitropress [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867709"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Nipride</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F202230"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F202200"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;">
<b>Note: Safety: </b>Use may be limited due to risk for cyanide and thiocyanate toxicity, which is increased with higher doses (eg, &gt;2 mcg/kg/minute) and/or prolonged duration of use, especially in patients with kidney or hepatic impairment. Invasive blood pressure monitoring, preferably via arterial line in a critical care unit, is recommended for appropriate dose titration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7069f2f-716f-4539-aa40-39abab340257">Acute aortic syndromes/acute aortic dissection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute aortic syndromes/acute aortic dissection (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Manage patients on an emergency basis (including operative assessment) by first controlling pain with IV opioids and heart rate (target 60 to 80 beats per minute) with a parenteral beta blocker (eg, esmolol) while targeting systolic BP of &lt;120 mm Hg (or lowest tolerated pressure without compromising perfusion). If systolic BP remains elevated after heart rate is controlled at 60 to 80 beats per minute with beta-blockade, may consider adding a vasodilator (eg, nitroprusside) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322642','lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322642','lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV:</b> Initial: 0.25 to 0.5 mcg/kg/minute; titrate as needed by 0.5 mcg/kg/minute every 5 minutes to achieve desired hemodynamic effect; maximum dose: 10 mcg/kg/minute. Higher doses (eg, 8 to 10 mcg/kg/minute) should only be used for a maximum of 10 minutes; use for the shortest duration possible to avoid toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Elliot.1','lexi-content-ref-17565029','lexi-content-ref-31693807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Elliot.1','lexi-content-ref-17565029','lexi-content-ref-31693807'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="544fdb8d-9360-4b5b-be1d-3c8dd40a45be">Acute decompensated heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute decompensated heart failure (adjunctive agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May consider in patients with volume overload in the absence of symptomatic hypotension to help relieve congestion and dyspnea as an adjunct to IV diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: IV:</b> Initial: 0.1 to 0.3 mcg/kg/minute; titrate as needed every 5 to 15 minutes to achieve desired hemodynamic effect; usual dosage range: 1 to 3 mcg/kg/minute; maximum dose: 5 mcg/kg/minute for an 80 kg patient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21164062','lexi-content-ref-18158484','lexi-content-ref-17447137','lexi-content-ref-18617068','lexi-content-ref-22281246','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21164062','lexi-content-ref-18158484','lexi-content-ref-17447137','lexi-content-ref-18617068','lexi-content-ref-22281246','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4321da4-681e-4b90-ad74-21ac966a29fd">Acute ischemic stroke, BP management with reperfusion therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute ischemic stroke, BP management with reperfusion therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>During and 24 hours after reperfusion therapy, maintain a target BP of <b>≤180/105 mm Hg</b>; reserve nitroprusside for hypertension that is refractory to first-line agents or diastolic BP &gt;140 mm Hg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV:</b> Initial: 0.25 to 0.5 mcg/kg/minute; titrate by 0.5 mcg/kg/minute every 5 minutes. Maximum dose: 10 mcg/kg/minute (for a maximum of 10 minutes); consider a maximum dose of 2 mcg/kg/minute to avoid toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30734342','lexi-content-ref-17565029','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30734342','lexi-content-ref-17565029','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a669e060-0890-4fb4-a8f4-02d01c746a9b">Hypertensive emergency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use when preferred agents with less toxicity are unavailable. In general, reduce mean arterial blood pressure gradually by ~10% to 20% over the first hour, then by an additional 5% to 15% over the next 23 hours, unless there is a compelling indication for more rapid blood pressure and heart rate control (eg, acute aortic dissection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Elliot.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Elliot.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: IV: </b>Initial: 0.25 to 0.5 mcg/kg/minute; titrate as needed by 0.5 mcg/kg/minute every 5 minutes to achieve the target blood pressure; to avoid toxicity, limit dose to ≤2 mcg/kg/minute if possible; maximum dose: 10 mcg/kg/minute. Higher doses (eg, 8 to 10 mcg/kg/minute) should only be used for a maximum of 10 minutes; use for the shortest duration possible to avoid toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Elliot.1','lexi-content-ref-17565029','lexi-content-ref-31693807','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Elliot.1','lexi-content-ref-17565029','lexi-content-ref-31693807','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990670"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use in patients with kidney impairment may lead to the accumulation of thiocyanate and subsequent toxicity; limit use.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Limit mean infusion rate to &lt;3 mcg/kg/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Anuric patients: Limit mean infusion rate to 1 mcg/kg/minute.</p></div>
<div class="block doha drugH1Div" id="F50987912"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling; due to the risk of cyanide toxicity, use with caution.  </p></div>
<div class="block doe drugH1Div" id="F202201"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F202218"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12648" href="/d/html/12648.html" rel="external">see "Nitroprusside: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Increased infusion rates and prolonged use have been associated with increased cyanide concentrations and cyanide toxicity; monitor cyanide levels with prolonged use (eg, &gt;72 hours); coadministration with sodium thiosulfate is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011','lexi-content-ref-31871244','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011','lexi-content-ref-31871244','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9acf630a-2ca8-439f-a354-eba6f53c124f">Hypertension, acute including hypertensive crisis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, acute including hypertensive crisis:</b> Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.3 to 0.5 mcg/kg/minute; titrate every 5 minutes to desired effect; usual dose: 3 mcg/kg/minute; maximum dose: 10 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011','lexi-content-ref-31871244','lexi-content-ref-Park.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011','lexi-content-ref-31871244','lexi-content-ref-Park.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58d566bf-a6bb-4df1-96ba-e695cca1ee93">Cardiac output maintenance/stabilization, postresuscitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac output maintenance/stabilization, postresuscitation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.3 to 1 mcg/kg/minute; titrate to desired effect; maximum dose: 8 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51131230"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: Use in patients with renal impairment may lead to the accumulation of thiocyanate and subsequent toxicity; limit use and monitor thiocyanate blood concentrations:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Limit mean infusion rate to &lt;3 mcg/kg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Anuric patients: Limit mean infusion rate to 1 mcg/kg/minute.</p></div>
<div class="block dohp drugH1Div" id="F51131231"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; due to the risk of cyanide toxicity, use with caution.</p></div>
<div class="block adr drugH1Div" id="F202169"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Bradycardia, ECG changes, flushing, palpitations, severe hypotension, substernal pain, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Apprehension, dizziness, headache, increased intracranial pressure, restlessness</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, localized erythematous streaking, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hypothyroidism</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, intestinal obstruction, nausea, retching</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Decreased platelet aggregation, methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Irritation at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Muscle twitching</p></div>
<div class="block coi drugH1Div" id="F202185"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of compensatory hypertension (aortic coarctation, arteriovenous shunting); to produce controlled hypotension during surgery in patients with known inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) requiring emergency surgery; acute heart failure associated with reduced systemic vascular resistance (eg, septic shock); congenital (Leber's) optic atrophy or tobacco amblyopia; concomitant use with avanafil, sildenafil, tadalafil, vardenafil, or riociguat</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindication (not in US labeling): Hypersensitivity to nitroprusside or any component of the formulation; uncorrected anemia or hypovolemia; hepatic disease; severe kidney disease; disease states associated with vitamin B<sub>12</sub> deficiency</p></div>
<div class="block war drugH1Div" id="F202166"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cyanide toxicity: <b>[US Boxed Warning]: Except when used briefly or at low (&lt;2 mcg/kg/minute) infusion rates, nitroprusside gives rise to large cyanide quantities. Do not use the maximum dose for more than 10 minutes; if blood pressure is not controlled by the maximum rate (ie, 10 mcg/kg/minute) after 10 minutes, discontinue infusion. Monitor for cyanide toxicity via acid-base balance and venous oxygen concentration; however, clinicians should note that these indicators may not always reliably indicate cyanide toxicity. </b> Patients at risk of cyanide toxicity include those who are malnourished, have hepatic impairment, or those undergoing cardiopulmonary bypass, or therapeutic hypothermia (Rindone 1992). Discontinue use of nitroprusside if signs and/or symptoms of cyanide toxicity (eg, metabolic acidosis, decreased oxygen saturation, bradycardia, confusion, convulsions) occur. Although not routinely done, sodium thiosulfate has been co-administered with nitroprusside using a 10:1 ratio of sodium thiosulfate to nitroprusside when higher doses of nitroprusside are used (eg, 4 to 10 mcg/kg/minute) for extended periods of time in order to prevent cyanide toxicity (Shulz 2010; Varon 2008); thiocyanate toxicity may still occur with this approach (Rindone 1992). The use of other agents (eg, clevidipine, labetalol, nicardipine) should be considered if blood pressure is not controlled with nitroprusside.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: <b>[US Boxed Warning]: Excessive hypotension resulting in compromised perfusion of vital organs may occur; continuous blood pressure monitoring by experienced personnel is required. </b></p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intracranial pressure: Use may elevate intracranial pressure; in patients whose intracranial pressure is already elevated, use only with extreme caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Methemoglobinemia: Nitroprusside can cause a dose-dependent conversion of hemoglobin to methemoglobin. Methemoglobinemia should be suspected in any patient receiving &gt;10 mg/kg of nitroprusside and exhibiting signs of impaired oxygen delivery despite adequate cardiac output and arterial pO<sub>2</sub>. Symptomatic patients, regardless of methemoglobin level should be treated with methylene blue (first-line). Treatment is suggested if level is ≥30% even if asymptomatic unless patient has a preexisting condition (eg, coronary artery disease) and are incapable of tolerating reductions in oxygen carrying capacity then treatment is suggested if level reaches 10% (Cortazzo 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thiocyanate toxicity: Can occur in patients with kidney impairment or those on prolonged infusions (ie, &gt;3 mcg/kg/minute for &gt;72 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing anemia prior to use when possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypovolemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing hypovolemia prior to use when possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with extreme caution in patients with kidney impairment; use the lowest end of the dosage range; monitor thiocyanate concentrations closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myocardial infarction: Use caution in patients with acute myocardial infarction because of hemodynamic effects and possible coronary steal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: Nitropress: <b>[US Boxed Warning]: Solution must be further diluted with 5% dextrose in water. Do not administer by direct injection.</b></p></div>
<div class="block foc drugH1Div" id="F202177"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nipride RTU: 20 mg/100 mL in NaCl 0.9% (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nitropress: 25 mg/mL (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (2 mL); 50 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nipride RTU: 50 mg/100 mL in NaCl 0.9% (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F202162"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323524"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nipride RTU Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/100 mL 0.9% (per mL): $0.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/100 mL 0.9% (per mL): $0.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nitroprusside Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $9.75 - $161.82</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867710"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nipride: 25 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (2 mL)</p></div>
<div class="block adm drugH1Div" id="F202182"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: IV infusion only; infusion pump required. Due to potential for excessive hypotension, continuously monitor patient’s blood pressure during therapy. Product should always be protected from light, even during administration.</p></div>
<div class="block admp drugH1Div" id="F52613437"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer as a continuous IV infusion via infusion pump. Solution should be protected from light, but not necessary to wrap administration set or IV tubing.</p>
<p style="text-indent:-2em;margin-left:2em;">Concentrated solution (25 <b>mg</b>/mL): Not for direct injection; <b>must dilute</b> prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Premixed solutions (200 mcg/mL, 500 mcg/mL): No further dilution required.</p></div>
<div class="block uica drugH1Div" id="F14473001"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 50 mg in 250 mL (concentration: 200 <b>mcg</b>/mL) <b>or</b> 100 mg in 250 mL (concentration: 400 <b>mcg</b>/mL) of D<sub>5</sub>W</p></div>
<div class="block uicp drugH1Div" id="F14473002"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 100 <b>mcg</b>/mL <b>or</b> 200 <b>mcg</b>/mL.</p></div>
<div class="block use drugH1Div" id="F202181"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute decompensated heart failure:</b> Management of acute decompensated heart failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency:</b> Management of hypertensive crises; used for controlled hypotension to reduce bleeding during surgery.</p></div>
<div class="block off-label drugH1Div" id="F25469127"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute aortic syndromes/acute aortic dissection; Acute ischemic stroke, BP management with reperfusion therapy</p></div>
<div class="block mst drugH1Div" id="F202238"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nitroprusside may be confused with nitroglycerin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299769"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F202171"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Nitroprusside.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Nitroprusside.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: May enhance the hypotensive effect of Nitroprusside.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13263869"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal studies have shown that nitroprusside may cross the placental barrier and result in fetal cyanide levels that are dose-related to maternal nitroprusside levels.  However, information related to use in pregnancy is limited.</p></div>
<div class="block brc drugH1Div" id="F20617180"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if nitroprusside is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F202175"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure via arterial line and heart rate (cardiac monitor and blood pressure monitor required) (Friedrich 1995); monitor for cyanide and thiocyanate toxicity; monitor venous oxygen saturation; monitor acid-base status as acidosis can be the earliest sign of cyanide toxicity; monitor thiocyanate levels if requiring prolonged infusion (&gt;3 days) or dose &gt;3 mcg/kg/minute or patient has kidney dysfunction; monitor cyanide blood levels (if available with appropriate turnaround time) in patients with decreased hepatic function</p>
<p style="text-indent:0em;margin-top:2em;">Consult individual institutional policies and procedures.</p></div>
<div class="block rer drugH1Div" id="F202178"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Serum thiocyanate levels are not helpful in detecting toxicity. A level may be confirmatory if a patient is exhibiting signs and symptoms of thiocyanate toxicity. Initial signs of toxicity (eg, tinnitus) may be observed at levels &gt;35 mcg/mL (manufacturer suggests 60 mcg/mL), but serious toxicity typically may not occur with levels &lt;100 mcg/mL.</p></div>
<div class="block pha drugH1Div" id="F202165"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Causes peripheral vasodilation by direct action on venous and arteriolar smooth muscle, thus reducing peripheral resistance; will increase cardiac output by decreasing afterload; reduces aortal and left ventricular impedance</p></div>
<div class="block phk drugH1Div" id="F202184"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Hypotensive effect: &lt;2 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Hypotensive effect: 1-10 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Nitroprusside combines with hemoglobin to produce cyanide and cyanmethemoglobin. Cyanide detoxification occurs via rhodanase-mediated conversion of cyanide to thiocyanate; rhodanase couples cyanide molecules to sulfane sulfur groups from a sulfur donor (eg, thiosulfate, cystine, cysteine). This process has limited capacity and may become overwhelmed with large exposures once sulfur donor supplies are exhausted resulting in toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Nitroprusside, circulatory: ~2 minutes; Thiocyanate, elimination: ~3 days (may be doubled or tripled in renal failure) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as thiocyanate)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F202187"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Nitropress</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Niprusodio | Nitroprusiato de sodio gemepe</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nitrop</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nipruss</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nitropress</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Nitroprusiato de sodio | Prusiat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nipride</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nitropress</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Nitropress</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nipride</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Nitopro</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nipride</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nipride</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Nipruss</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Nipride</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cordibux | Dorespin | Nitroprusiato de sodio</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Nipride | Sodium nitroprusside</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nitropress | Nitroprusside sagent</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sodium nitroprusside</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clenil | Nitropress</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nipride rtu | Nitropress | Sodium nitroprusside</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nitropress</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Nanipruss</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">DBL sodium nitroprusside</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nipruss | Nitropress</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nipride | Nipruss</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Niprusodio fada</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nitroprusiato</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed January 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3917495">
<a name="3917495"></a>Benitz WE, Malachowski N, Cohen RS, et al. Use of Sodium Nitroprusside in Neonates: Efficacy and Safety. <i>J Pediatr</i>. 1985;106(1):102-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/3917495/pubmed" id="3917495" target="_blank">3917495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cachat.1">
<a name="Cachat.1"></a>Cachat F, Guignard JP. Reply to the letter from C. von Schnakenburg and M. Krüger. <i>Pediatr Nephrol.</i> 2004;19:1308-1309.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21164062">
<a name="21164062"></a>Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart failure syndromes. <i>Am J Health Syst Pharm</i>. 2011;68(1):21-35. doi:10.2146/ajhp100202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/21164062/pubmed" id="21164062" target="_blank">21164062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23953868">
<a name="23953868"></a>Cortazzo JA, Lichtman AD. Methemoglobinemia: a review and recommendations for management. <i>J Cardiothorac Vasc Anesth</i>. 2014;28(4):1043-1047. doi:10.1053/j.jvca.2013.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/23953868/pubmed" id="23953868" target="_blank">23953868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21773822">
<a name="21773822"></a>Chandar J, Zilleruelo G. Hypertensive crisis in children. <i>Pediatr Nephrol</i>. 2012;27(5):741-751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/21773822/pubmed" id="21773822" target="_blank">21773822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30734342">
<a name="30734342"></a>Der-Nigoghossian C, Levasseur-Franklin K, Makii J. Acute blood pressure management in neurocritically ill patients. <i>Pharmacotherapy</i>. 2019;39(3):335-345. doi:10.1002/phar.2233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/30734342/pubmed" id="30734342" target="_blank">30734342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18158484">
<a name="18158484"></a>Elkayam U, Janmohamed M, Habib M, Hatamizadeh P. Vasodilators in the management of acute heart failure. <i>Crit Care Med</i>. 2008;36(1)(suppl):S95-S105. doi:10.1097/01.CCM.0000297161.41559.93<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/18158484/pubmed" id="18158484" target="_blank">18158484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliot.1">
<a name="Elliot.1"></a>Elliot WJ, Varon J. Drugs used for the treatment of hypertensive emergencies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 23, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliot.2">
<a name="Elliot.2"></a>Elliot WJ, Varon J. Evaluation and treatment of hypertensive emergencies in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10669188">
<a name="10669188"></a>Erstad BL, Barletta JF. Treatment of Hypertension in the Perioperative Patient. <i>Ann Pharmacother</i>. 2000;34(1):66-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/10669188/pubmed" id="10669188" target="_blank">10669188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10775081">
<a name="10775081"></a>Flynn JT. Neonatal hypertension: diagnosis and management. <i>Pediatr Nephrol</i>. 2000;14(4):332-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/10775081/pubmed" id="10775081" target="_blank">10775081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29192011">
<a name="29192011"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/29192011/pubmed" id="29192011" target="_blank">29192011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7598246">
<a name="7598246"></a>Friederich JA, Butterworth JF 4th. Sodium nitroprusside: twenty years and counting. <i>Anesth Analg</i>. 1995;81(1):152-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/7598246/pubmed" id="7598246" target="_blank">7598246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19800251">
<a name="19800251"></a>Furck AK, Hansen JH, Uebing A, et al. The Impact of Afterload Reduction on the Early Postoperative Course After the Norwood Operation - A 12-year Single-Centre Experience. <i>Eur J Cardiothorac Surg</i>. 2010;37(2):289-295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/19800251/pubmed" id="19800251" target="_blank">19800251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17447137">
<a name="17447137"></a>Hollenberg SM. Vasodilators in acute heart failure. <i>Heart Fail Rev</i>. 2007;12(2):143-147. doi:10.1007/s10741-007-9017-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/17447137/pubmed" id="17447137" target="_blank">17447137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6499856">
<a name="6499856"></a>Ihlen H, Myhre E, Opstad P. Evaluation of Potential Adverse Effects of Sodium Nitroprusside During Pacing-Induced Myocardial Ischaemia in Man. <i>Eur Heart J</i>. 1984;5(10):834-841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/6499856/pubmed" id="6499856" target="_blank">6499856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322642">
<a name="36322642"></a>Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. <i>Circulation.</i> 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/36322642/pubmed" id="36322642" target="_blank">36322642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23370205">
<a name="23370205"></a>Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2013;44(3):870-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/23370205/pubmed" id="23370205" target="_blank">23370205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8602386">
<a name="8602386"></a>Johanning RJ, Zaske DE, Tschida SJ, et al. A retrospective study of sodium nitroprusside use and assessment of the potential risk of cyanide poisoning. <i>Pharmacotherapy</i>. 1995;15(6):773-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/8602386/pubmed" id="8602386" target="_blank">8602386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16616682">
<a name="16616682"></a>Kiran U, Zuber K, Kakani M. Combination of Low-Dose Phenoxybenzamine and Sodium Nitroprusside in Children Undergoing Cardiac Surgery. <i>J Cardiothorac Vasc Anesth</i>. 2006;20(2):291-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/16616682/pubmed" id="16616682" target="_blank">16616682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S876-S908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17565029">
<a name="17565029"></a>Marik PE, Varon J. Hypertensive crises: challenges and management. <i>Chest</i>. 2007;131(6):1949-1962. doi:10.1378/chest.06-2490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/17565029/pubmed" id="17565029" target="_blank">17565029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18957627">
<a name="18957627"></a>Moffett BS, Price JF. Evaluation of Sodium Nitroprusside Toxicity in Pediatric Cardiac Surgical Patients. <i>Ann Pharmacother</i>. 2008;42(11):1600-1604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/18957627/pubmed" id="18957627" target="_blank">18957627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15747270">
<a name="15747270"></a>Motta P, Mossad E, Toscana D, Zestos M, Mee R. Comparison of phenoxybenzamine to sodium nitroprusside in infants undergoing surgery. <i>J Cardiothorac Vasc Anesth</i>. 2005;19(1):54-59. doi:10.1053/j.jvca.2004.11.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/15747270/pubmed" id="15747270" target="_blank">15747270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617068">
<a name="18617068"></a>Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. <i>J Am Coll Cardiol</i>. 2008;52(3):200-207. doi:10.1016/j.jacc.2008.02.083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/18617068/pubmed" id="18617068" target="_blank">18617068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations.<i> Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nipride.1">
<a name="Nipride.1"></a>Nipride RTU (sodium nitroprusside) [prescribing information]. Lenoir, NC: Exela Pharma Sciences LLC; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nipride.2">
<a name="Nipride.2"></a>Nipride (sodium nitroprusside) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitropress.1">
<a name="Nitropress.1"></a>Nitropress (sodium nitroprusside injection) [prescribing information]. McPherson, KS: Hospira Inc; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitropress.2">
<a name="Nitropress.2"></a>Nitropress injection (nitroprusside) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xiromed.1">
<a name="Xiromed.1"></a>Nitroprusside Sodium [prescribing information]. Florham Park, NJ: Xiromed LLC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1089194">
<a name="1089194"></a>Palmer RF, Lasseter KC. Drug Therapy: Sodium Nitroprusside. <i>N Engl J Med</i>. 1975;292(6):294-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/1089194/pubmed" id="1089194" target="_blank">1089194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.2">
<a name="Park.2"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021:972.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693807">
<a name="31693807"></a>Peixoto AJ. Acute severe hypertension. <i>N Engl J Med</i>. 2019;381(19):1843-1852. doi:10.1056/NEJMcp1901117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/31693807/pubmed" id="31693807" target="_blank">31693807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. <i>Am J Health Syst Pharm</i>. 2011;68(22):2176-2182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31662037">
<a name="31662037"></a>Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/31662037/pubmed" id="31662037" target="_blank">31662037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1907977">
<a name="1907977"></a>Pramar Y, Das Gupta V, Gardner SN, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. <i>J Clin Pharm Ther</i>. 1991;16(3):203-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/1907977/pubmed" id="1907977" target="_blank">1907977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19635770">
<a name="19635770"></a>Rhoney D, Peacock WF,. Intravenous Therapy for Hypertensive Emergencies, Part 1. <i>Am J Health-Syst Pharm</i>. 2009;66(15):1343-1352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/19635770/pubmed" id="19635770" target="_blank">19635770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1533553">
<a name="1533553"></a>Rindone JP, Sloane EP. Cyanide toxicity from sodium nitroprusside: risks and management. <i>Ann Pharmacother</i>. 1992;26:515-519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/1533553/pubmed" id="1533553" target="_blank">1533553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22281246">
<a name="22281246"></a>Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. <i>J Am Coll Cardiol</i>. 2012;59(5):442-451. doi:10.1016/j.jacc.2011.09.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/22281246/pubmed" id="22281246" target="_blank">22281246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21625332">
<a name="21625332"></a>Shulz LT, Elder EJ, Jones KJ, et al. Stability of Sodium nitroprusside and sodium thiosulfate 1:10 intravenous admixture. <i>Hosp Pharm</i>. 2010;45(10):779-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/21625332/pubmed" id="21625332" target="_blank">21625332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18257607">
<a name="18257607"></a>Varon J. Treatment of acute severe hypertension. <i>Drugs</i>. 2008;68(3):283-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/18257607/pubmed" id="18257607" target="_blank">18257607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3970795">
<a name="3970795"></a>Vesey CJ, Cole PV. Blood Cyanide and Thiocyanate Concentrations Produced by Long-Term Therapy With Sodium Nitroprusside. <i>Br J Anaesth</i>. 1985;57(2):148-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/3970795/pubmed" id="3970795" target="_blank">3970795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3993700">
<a name="3993700"></a>Wesson DE, Foley R, Sabatini S, et al. Treatment of Acute Cyanide Intoxication With Hemodialysis. <i>Am J Nephrol</i>. 1985;5(2):121-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/3993700/pubmed" id="3993700" target="_blank">3993700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7880995">
<a name="7880995"></a>Williams RS, Mickell JJ, Young ES, et al. Methemoglobin Levels During Prolonged Combined Nitroglycerin and Sodium Nitroprusside Infusions in Infants After Cardiac Surgery. <i>J Cardiothorac Vasc Anesth</i>. 1994;8(6):658-662. doi:10.1016/1053-0770(94)90198-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/7880995/pubmed" id="7880995" target="_blank">7880995</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9707 Version 359.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
